ベトナムの医薬品有効成分（API）市場 – 業界動向と2030年までの予測

ベトナムの医薬品有効成分（API）市場分析と規模

医薬品有効成分（API）には、安全で効果的な製品に対するニーズの高まりなどの特徴があり、メーカーによる新製品の市場投入に影響を与え、需要が高まるとともに研究開発への投資も増加し、市場の成長につながります。医薬品有効成分の開発に関する研究への投資の増加は、医薬品有効成分（API）市場にさまざまな機会をもたらすと予想されます。ただし、標準以下の医薬品や偽造医薬品の流通と製造コストの高さにより、予測期間中の市場の成長は抑制されると予想されます。

The active pharmaceutical ingredients (API) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. On the other hand, strategic initiatives by market players and the rise in the agriculture field and in the food and beverages industries may act as an opportunity for the growth of the Vietnam active pharmaceutical ingredients (API) market. The risks associated with over usage of phosphate-based products may create challenges for the Vietnam active pharmaceutical ingredients (API) market. There are some recent developments related to the Vietnam active pharmaceutical ingredients (API) market.

Vietnam active pharmaceutical ingredients (API) market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.1% in the forecast period of 2023 to 2030 and is expected to reach USD 101,174.22 million by 2030. The increasing prevalence of various chronic disorders and the increase in the aging population are the major drivers that propelled the demand of the market in the forecast period.

Data Bridge Market Research analyzes that the Vietnam active pharmaceutical ingredients (API) market is expected to reach the value of USD 101,174.22 million by 2030, at a CAGR of 8.1%. The antibiotics segment is the largest product segment in the market due to the rising prevalence of chronic disease, which can be expected to increase the demand of APIs and increase the growth of the Vietnam active pharmaceutical ingredients (API) market.

Market Definition

In Greek, the traditional word for active pharmaceutical ingredients (API) is called pharmacon or pharmakon, which symbolizes a magical substance or drug. Active pharmaceutical ingredients as described in ICH Q7, is “any substance or combination of substances intended to be used in the manufacturing of a drug product, which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity. When more than one APIs is added to the drug, then it produces various therapeutic activities and can be used for the treatment of various diseases and control their symptoms. A small amount of active pharmaceutical ingredients is effective in providing a therapeutic effect in the body. The active pharmaceutical ingredients go under chemical changes during the manufacturing of the APIs, and then it is present in the finished drug product in a modified form to provide a specific therapeutic effect.

Vietnam Active Pharmaceutical Ingredients (API) Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Drivers

Increasing Prevalence of Various Chronic Disease

The high prevalence of chronic diseases such as diabetes, cardiovascular disease, respiratory diseases and others is expected to drive the active pharmaceutical ingredients (API) market. The burden of chronic disease is affecting the population in different of the globe, such as Vietnam, China, Mongolia etc., at a rapid rate all over the world and worsening the health and quality of the people's life. Chronic diseases involving diabetes, heart disease, respiratory disease, arthritis, Parkinson’s disorder, multiple sclerosis, and Alzheimers among others, can lead to long-term disability and also worsens the health of people in Vietnam.

In Vietnam, the incidence of diabetes has been increasing at an alarming rate, with it doubling in the past 10 years. The number of pre-diabetics has also increased by three times as many as there are diabetics.

• Despite diabetes incidence rates decreasing for the majority of racial/ethnic groups, rates for Vietnamese-American women are increasing
• The mortality of cancer and diabetes has been shown to increase for Vietnamese Americans on temporal trends
• 1 in 17 Vietnamese adults (1 in 15 men and 1 in 20 women) has diabetes

Thus, this signifies that with the high prevalence of chronic disorders, the demand for the development and innovation of active pharmaceutical ingredients (API) is increasing, hence, leading to the growth of the Vietnam active pharmaceutical ingredients (API) market over the forecast period.

Restraint

High Manufacturing Cost

The APIs manufacturing cost is considered as one of the costly investments to meet the standards of the cGMP as well as the World Health Organization (WHO) GMP and SRL. The manufacturing cost of the APIs production is increased due to some of the reasons given below:

• In order to improve the manufacturing facilities and replacing the old technologies with the advanced one for the production of APIs can be costly for the manufacturers as the cost for the advanced technologies are high as compared to others
• The advanced technologies need highly qualified personnel who can work with these technologies. The processes, dossier of the product efficacy as well as safety test that has to meet the regulatory bodies’ requirement sometimes is costly for the manufacturers, especially for those who are involved in the small-scale manufacturing
• The cost for the procurement of the regulatory approvals from the regulatory bodies is considered as one of the factors for the high manufacturing cost of APIs. The regulatory approvals are mainly costly for those firms who are involved in the manufacturing of small volumes of APIs that is for small-scale manufacturers

Therefore, the high manufacturing cost can act as a restraint factor for the growth of active pharmaceutical ingredients (API), especially for the small-scale manufacturers and for the new entrants as they have to take the FDA approvals, research and development start-up costs which is around USD 11.00 billion to USD 12.00 billion depending on which APIs have been discovered by the manufacturers which can decline the growth of the Vietnam active pharmaceutical ingredients (API) market. 

Opportunity

Increasing Healthcare Expenditure

The government is continuously engaged in the activity for improving healthcare facilities to provide better health facilities and treatment to the patients. Both public and private sector companies play a vital role in improving the healthcare sector, providing health benefits to individuals. There is a close association between a country's total income levels and how much that country's government spends on population health.

With an aim to allow access to available treatments, the government is focusing towards increasing healthcare expenditure.

The greater the healthcare expenditure of a country, the lower is the chances of disease and non-operated deaths in that country which plays an important role in the development of the overall country. The increased healthcare expenditure renders the patients to get acquainted with the advanced and novel drugs formulated from innovative APIs needed by them in order to achieve better therapies so as to attain a healthier life. The manufacturing companies will also take initiatives to develop APIs using the advanced technology as the healthcare expenditure is increased worldwide

Challenge

Lack of Workforce in Pharma Industries

There is a large number of manufacturing companies who are involved in API production and nowadays, technology has increased, which needs a properly skilled and technical workforce for the production of APIs. But the increasing demand and complexity with newly developed technologies for API production put a challenge in front of manufacturers.

For Instance,

• According to World Economic Forum Lighthouses project, the pharma companies have a shortage of skilled workforce which creates a barrier for scaling the novel technologies. There is a gap between pharma companies and skilled workforce and the people are not upgraded due to the increase in high technologies
• According to a published report in March 2022, Vietnam’s Hiring Challenges and Potential Incentives for Retaining Employees. FDI firms continue to struggle in hiring skilled labor in Vietnam. Major challenges include the lack of technology infrastructure, R&D spending, vocational and technical skills. The lack of skilled labor has the potential to slow down the economic transition from labor-intensive industries to high-tech goods, reducing Vietnam’s competitiveness. Thus, the government should introduce reforms in education and industrial training to meet current industry demands

Moreover, everyday changing technologies put a challenge for the manufacturers to perform the production. A lack of skilled lab professionals leads to inaccurate production of APIs and makes the process tedious and cumbersome, which poses difficulty to manufacturers. Therefore, the lack of workforce acts as a challenge for the growth of the Vietnam Active Pharmaceutical Ingredients (API) market.

Recent Developments

• In January 2021, Sanofi had announced the name of the European company, EUROAPI that will manufacture as well as commercialize the active pharmaceutical ingredients. This company will be considered as one of the largest API production in Europe. The APIs will be marketed in Europe as well as in other parts of the regions. This helped the company to expand their business worldwide in the terms of active pharmaceutical ingredients which will increase their market revenues in coming future
• In April 2020, Dr. Reddy’s Laboratories Ltd. has received the EIR that is establishment inspection report from the U.S. healthcare regulator. The company has received the EIR for active pharmaceutical manufacturing unit established in Nalgonda. EIR received by the USFDA when the inspection done by USDFDA is satisfactory and the facilities available in the manufacturing plant is up to the mark. This EIR approval helped the company to boost up their manufacturing facilities which will increase their production of products at the end
• In February 2020, Sanofi had announced their plans that they will create a European company which is based on the manufacturing and marketing of the active pharmaceutical ingredients. These APIs will be marketed to the third parties of APIs. The company has decided that it will be a standalone company along with the Sanofi’s API manufacturing and marketing activities. The motive behind the company was to decrease the shortage of the APIs in the market. This helped the company to increase their growth in the market related to APIs especially from the third party sales

Vietnam Active Pharmaceutical Ingredients (API) Market Scope

Vietnam active pharmaceutical ingredients (API) market is segmented into ten notable segments such as, therapeutic class, type, type of manufacturer, synthesis, potency, type of drug, molecule, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

By Therapeutic Class

• Antibiotic
• Cardiovascular
• Lipid Lowering Drugs
• Infectious Disease
• Anesthetic
• NSAIDS
• Analgesic
• Antiviral
• Dermatology
• Oncology
• Endocrinology
• Urology
• Gastroenterology
• Ophthalmology
• Hormonal Agents
• Muscle Relaxant
• Parkinson
• Psoriasis
• Epileptic
• Immunology
• Hematology
• Antineoplastic
• Immunosuppressive Agents
• Others

On the basis of product Vietnam active pharmaceutical ingredients (API) market is segmented into antibiotics are cardiovascular, lipid lowering drugs, infectious disease, anesthetic, NSAIDs, analgesic, antiviral, dermatology, oncology, endocrinology, urology, gastroenterology, ophthalmology, hormonal agents, muscle relaxant, parkinson, psoriasis, epileptic, immunology, hematology, antineoplastic, immunosuppressive agents, and others Vietnam Active Pharmaceutical Ingredients (API) market.

By Type

• Innovative Active Pharmaceutical Ingredient
•  Generic Active Pharmaceutical Ingredient

On the basis of type, the Vietnam active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredient and generic Active Pharmaceutical Ingredients.

By Type Of Manufacturer

• Captive Manufacturers
•  Merchant Manufacturers

On the basis of type of manufacturer, the Vietnam active pharmaceutical ingredients (API) market is segmented into captive manufacturers and merchant manufacturers.

By Synthesis

• Chemical Synthetic
•  Biotech

On the basis of synthesis, the Vietnam active pharmaceutical ingredients (API) market is segmented into chemical synthetic and biotech.

By Potency

• Traditional Potency Active Pharmaceutical Ingredient
•  High Potency Active Pharmaceutical Ingredient

On the basis of Potency, the Vietnam active pharmaceutical ingredients (API) market is segmented into traditional potency active pharmaceutical ingredients and high potency active pharmaceutical ingredients.

By Type Of Drug

• Prescription Drugs
•  Over-The-Counter Drugs

On the basis of type of drug, the Vietnam active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs.

By Molecule

• Small Molecule
• Large Molecule

On the basis of molecule, the Vietnam active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule.

By Application

• Clinical 
•  Research

On the basis of application, the Vietnam active pharmaceutical ingredients (API) market is segmented into clinical and research.

By End User

• Pharmaceutical Industries
•  Biotechnology Industries
•  Research and Academic Institutes
•  Others

On the basis of end user, the Vietnam active pharmaceutical ingredients (API) market is segmented into pharmaceutical industries, biotechnology industries, research and academic institutes, and others.

By Distribution Channel

• Direct Tenders
•  Retail Sales
•  Others

On the basis of distribution channel, the Vietnam active pharmaceutical ingredients (API) market is segmented into direct tenders, retail sales and others.

Vietnam Active Pharmaceutical Ingredients (API) Market Regional Analysis/Insights

The Vietnam active pharmaceutical ingredients (API) market is segmented into ten notable segments such as therapeutic class, type, type of manufacturer, synthesis, potency, type of drug, molecule, application, end user, and distribution channel.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、リンとその誘導体の存在と可用性、および厳格な規制によって直面する課題も考慮されます。

競争環境とベトナムの医薬品有効成分（API）市場シェア分析

ベトナムの原薬 (API) 市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、事業拡大、サービス施設、パートナーシップ、戦略的開発、アプリケーションの優位性、および技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、ベトナムの原薬 (API) 市場に対する会社の重点にのみ関連しています。

ベトナムの医薬品有効成分（API）市場で活動している主要企業としては、Dr. Reddy's Laboratories Ltd.、Sanofi、Pfizer Inc.、GSK plc、Aurobindo Pharma、AstraZeneca、Novo Nordisk A/S、Unichem Laboratorie、Jubilant Pharma Limited、MEKOPHAR、Lupin、Sun Pharmaceutical Industries Ltd.、Divi's Laboratories Limited、CH Boehringer Sohn AG & Co. KG、BASF SEなどが挙げられます。

SKU-69921